There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.

There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.

There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.

There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.

There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.

There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.

There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.

There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.

There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.

There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.